Edesa Biotech, Inc. (EDSA)

Over the past six months, Edesa Biotech's stock has been impacted by several events. In August 2025, the company reported its fiscal third-quarter results and advanced manufacturing activities for EB06. In October 2025, positive results were announced from a Phase 3 study for paridiprubart (EB05) in ARDS. In December 2025, Edesa Biotech reported its fiscal year 2025 results, initiated manufacturing activities for a Phase 2 study of EB06, explored partnerships for EB05, and increased its at-the-market offering limit; the company also reported -$0.365 earnings per share for the quarter, missing the consensus estimate of -$0.267, which led to a stock price decrease of -16.092%. In January 2026, Edesa management planned to participate in one-on-one meetings during JP Morgan week. In February 2026, Edesa Biotech is scheduled to report its fourth-quarter earnings. The stock price has experienced fluctuations, with a 52-week range between $0.94 and $4.49, and as of February 5, 2026, the share price was $1.12.

Edesa Biotech's product pipeline includes treatments for conditions that may exhibit some seasonality, particularly respiratory diseases like ARDS. Demand for EB05 could be influenced by the prevalence of respiratory infections, which often have seasonal patterns. For dermatology products like EB01 and EB06, direct seasonality of demand is not explicitly stated, but certain dermatological conditions can sometimes be exacerbated by environmental factors that vary seasonally.

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on acquiring, developing, and commercializing drugs for inflammatory and immune-related diseases. The company operates within the Biotechnology industry, focusing on Medical Dermatology and Respiratory diseases. Its major product candidates include EB05 (paridiprubart) for ARDS, EB01 (1.0% daniluromer cream) for chronic allergic contact dermatitis, EB06 for vitiligo, and EB07 for pulmonary fibrosis and systemic sclerosis. Edesa Biotech also holds license and collaboration agreements with NovImmune SA and Yissum Research Development Company.

Edesa Biotech, Inc. is headquartered in Markham, Ontario, Canada, and maintains U.S. offices in Southern California.

Information directly detailing Edesa Biotech's brand reputation in the past year is not explicitly available. However, securing funding from the Government of Canada and FDA Fast Track designation suggests a positive perception from regulatory bodies. Positive Phase 3 results for EB05 in October 2025 would likely enhance the company's scientific and clinical reputation. The company's focus on developing alternatives to steroids and JAK inhibitors positions them as an innovator seeking safer treatment options.

Edesa Biotech, Inc. has 26 institutional owners and shareholders holding a total of 2,868,209 shares. Approximately 32.98% of the company's stock is owned by institutional investors, while 16.62% is owned by insiders. Major institutional shareholders include Stonepine Capital Management, LLC, Rubric Capital Management LP, Velan Capital Investment Management LP, Nantahala Capital Management, LLC, Geode Capital Management, Llc, Vanguard Group Inc, Commonwealth Equity Services, Llc, Renaissance Technologies Llc, VEXMX - Vanguard Extended Market Index Fund Investor Shares, and Susquehanna International Group, Llp. Pardeep Nijhawan, the CEO, owns the most shares among individuals.